Owen Davis

Owen Davis studied chemistry at Imperial College London, going on to complete a PhD under the guidance of the now-Professor James Bull, focussing on the synthesis of highly substituted oxetanes. He then spent 3 years at the Institute of Cancer Research (ICR) for postdoctoral research under the now-Professor Swen Hoelder, designing inhibitors and degraders of BCL6. He moved to Artios Pharma in 2019, where he has worked on a range of DDR-based projects, including Artios’s nuclease targeting discovery platform, DNA polymerase theta and more recently the DDRi-ADC platform.